Skip to main content
๐ŸงฌPeptide Protocol Wiki

5-Amino-1MQ: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 75 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides โ†’

โœ“Reviewed byEditorial Team
๐Ÿ“…Updated February 18, 2026
Unverified

๐Ÿ“ŒTL;DR

  • โ€ข3 community protocols documented
  • โ€ขEvidence level: Anecdotal Reports
  • โ€ขBased on 75 community reports
  • โ€ข1 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

AspectClinical ApproachCommunity ApproachSignificance
Evidence BaseAll published studies on 5-Amino-1MQ are preclinical (cell culture and mouse models). No human pharmacokinetic, safety, or efficacy data has been published in peer-reviewed journals.Peptide therapy clinics and biohacking communities prescribe and use 5-Amino-1MQ based on extrapolation from preclinical data. Dosing is empirically determined without formal human dose-ranging studies.high

This is a critical divergence. There is no published human data to support any dose, duration, or safety claims for 5-Amino-1MQ. Community use is entirely experimental.

DosingMouse studies used doses of approximately 16 mg/kg intraperitoneally. No human equivalent dose has been established through clinical studies.Community doses of 50-150 mg daily are derived from unverified allometric scaling calculations and clinic experience. No published PK data supports these doses.high

Intraperitoneal dosing in mice does not translate directly to oral dosing in humans. Oral bioavailability of 5-Amino-1MQ in humans is unknown.

Purity and SourceResearch-grade 5-Amino-1MQ used in published studies is synthesized under controlled laboratory conditions with verified purity.Community members obtain 5-Amino-1MQ from compounding pharmacies or research chemical vendors. Purity and identity verification varies.moderate

As a relatively simple small molecule, 5-Amino-1MQ is less susceptible to degradation than peptides, but quality assurance depends entirely on the vendor.

Compare these community approaches with published research findings.

Community Protocols

Standard Oral Protocol

Popular
Route
Oral (capsule)
Dose
50 mg
Frequency
Once daily
Duration
8-12 weeks

Most commonly reported protocol from peptide therapy clinics; taken in the morning

Higher Dose Protocol

Common
Route
Oral (capsule)
Dose
100-150 mg
Frequency
Once daily (or split 50 mg 2-3x daily)
Duration
8-12 weeks

Some clinics prescribe higher doses; no published dose-response data in humans

Cycling Protocol

Niche
Route
Oral (capsule)
Dose
50-100 mg
Frequency
Once daily
Duration
8 weeks on, 4 weeks off

Cycling approach used by some biohackers; no evidence that cycling is necessary or beneficial

Stacking Patterns

5-Amino-1MQ + NAD+ Precursor Stack

Common

Dual NAD+ elevation via complementary mechanisms

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 75+ self-experimenters report. Free with email.

150+ peptide profiles ยท 30+ comparisons ยท 18 research tools

Already subscribed?

Sources

Community Evidence Overview#

5-Amino-1MQ has gained attention in peptide therapy clinics and biohacker communities as an NNMT inhibitor with potential metabolic and anti-aging benefits. Community evidence is classified as anecdotal level, reflecting the relatively small number of reports (approximately 75), absence of standardized protocols, and complete lack of published human clinical data.

Critical caveat: 5-Amino-1MQ has NO published human clinical trial data. All published evidence is preclinical (cell culture and mouse studies). Community use is entirely based on extrapolation from animal data. This section documents real-world usage patterns for informational purposes only and does not constitute endorsement of these protocols.

Protocol Divergence#

The central divergence for 5-Amino-1MQ is that community use exists entirely outside the bounds of published human research. Unlike most peptides on this site where community protocols diverge from clinical protocols, there are no clinical protocols to diverge from. Every aspect of human use โ€” dose, route, duration, and expected outcomes โ€” is based on preclinical extrapolation and empirical observation.

Community Protocols#

The most common protocol reported by peptide therapy clinics involves 50 mg taken orally once daily for 8-12 weeks. Some clinics prescribe 100-150 mg daily. These doses appear to derive from allometric scaling of mouse doses, though the specific calculations and assumptions are not published.

Commonly Reported Outcomes#

Community members report variable outcomes, including:

  • Modest improvements in energy and metabolism (commonly reported)
  • Gradual changes in body composition over 8-12 weeks (some reports)
  • Improved exercise recovery (occasional reports)
  • No dramatic acute effects or obvious side effects (consistent finding)

The subtlety of reported effects makes it difficult to distinguish drug effects from placebo, especially given the absence of controlled human trials.

Important Caveats#

  • No human clinical trials have been published for 5-Amino-1MQ
  • All dosing is based on preclinical extrapolation โ€” not established human pharmacology
  • Oral bioavailability in humans is unknown
  • Long-term safety in humans has not been evaluated
  • 5-Amino-1MQ is technically a small molecule, not a peptide, though it is commonly discussed alongside peptide therapies
  • Community reports are subject to significant placebo effect and confirmation bias

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.

150+ peptide profiles ยท 30+ comparisons ยท 18 research tools

Already subscribed?

Explore Further

โš ๏ธ

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.